Inhibiting Inflammation with Myeloid Cell-Specific Nanobiologics Promotes Organ Transplant Acceptance

An unresolved problem in organ transplantation is to establish graft acceptance in the absence of long-term immunosuppressive therapy. Braza et  al. unravel important molecular mechanisms underlying myeloid cell activation in an experimental organ transplantation model and develop a combined nanoimmunotherapy that targets myeloid cells in hematopoietic organs and the allograft. Short-term nanobiologic immunotherapy prevents inflammation an d induces indefinite allograft survival.

Source: Immunity - November 6, 2018 Category: Allergy & Immunology Authors: Mounia S. Braza, Mandy M.T. van Leent, Marnix Lameijer, Brenda L. Sanchez-Gaytan, Rob J.W. Arts, Carlos P érez-Medina, Patricia Conde, Mercedes R. Garcia, Maria Gonzalez-Perez, Manisha Brahmachary, Francois Fay, Ewelina Kluza, Susanne Kossatz, Regine J. Tags: Report Source Type: research